Guillermo Garcia-Manero

Guillermo Garcia-Manero, MD is Professor and Chief of the Section of Myelodysplastic Syndromes in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where he directs the largest single-institution MDS clinical research program in the United States. He is widely considered the preeminent MDS clinical investigator in North America, with a career spanning the development of virtually every modern MDS therapy. Dr. Garcia-Manero played a central role in the clinical development of decitabine (Dacogen) in MDS, leading the pivotal single-agent decitabine studies that established it as an effective option in MDS and generated data supporting its FDA approval (2006). He has led or co-led seminal trials examining optimized decitabine schedules (5-day versus 3-day), combinations with HDAC inhibitors, and sequencing strategies in both lower- and higher-risk MDS. At MD Anderson, he has developed and overseen a comprehensive phase I/II trial program that has evaluated more than 50 novel agents and combinations in MDS over the past two decades, generating landmark datasets in HMA failure, lower-risk MDS anemia, and TP53-mutated MDS. Dr. Garcia-Manero has contributed extensively to the molecular characterization of MDS, including the prognostic impact of SF3B1, TET2, ASXL1, DNMT3A, and RUNX1 mutations, and to the IPSS-M molecular scoring system. He has authored over 500 peer-reviewed publications, serves on the NCCN MDS and AML guidelines panels, and has mentored more than 100 MDS physicians worldwide.